Valion Bio, Inc.

Tivic Health Systems, Inc. is a late-stage biopharmaceutical company focused on developing Entolimod, a recombinant TLR5 agonist. Entolimod is being developed as a medical countermeasure for Acute Radiation Syndrome (ARS) and its related conditions, as well as an additional therapy for oncology indications like neutropenia. During fiscal year 2025, Tivic Health underwent a significant strategic change, shifting from a diversified bioelectronic medical device company to a focused biopharmaceutical company centered on its TLR5 agonist franchise. In February 2025, Tivic secured worldwide exclusive license rights and options for Entolimod and its second-generation compound, Entolasta. In December 2025, the company established Velocity Bioworks, a subsidiary contract development and manufacturing organization (CDMO) intended to support both Tivic and selected third-party clients. Concurrently, Tivic exited the consumer healthtech business and halted its prescription bioelectronic product development to concentrate resources on Entolimod. The company's current focus is on advancing Entolimod and Entolasta through regulatory approval for acute radiation syndrome and into government procurement, and expanding Entolimod's applications to oncology-related conditions such as neutropenia, thrombocytopenia, and general and specific mucositis. Tivic's common stock trades on The Nasdaq Capital Market under the symbol "TIVC." The company is headquartered in San Antonio, TX, and operates a Current Good Manufacturing Practice (CGMP)-compatible biomanufacturing facility in San Antonio, Texas, through Velocity Bioworks. The company uses a hybrid remote and on-site operational model.